Literature DB >> 21541705

Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells.

Erika Rimondi1, Maria Grazia di Iasio, Arianna Gonelli, Claudio Celeghini, Paola Secchiero, Giorgio Zauli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21541705     DOI： 10.1007/s10637-011-9675-8

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  19 in total

Review 1.  Putative biological roles of hydrogen sulfide in health and disease: a breath of not so fresh air?

Authors:  L Li; P K Moore
Journal:  Trends Pharmacol Sci       Date:  2008-01-03       Impact factor: 14.819

2.  Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?

Authors:  Rui Wang
Journal:  FASEB J       Date:  2002-11       Impact factor: 5.191

3.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

4.  An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

Authors:  Paola Secchiero; Federica Corallini; Assunta Pandolfi; Agostino Consoli; Riccardo Candido; Bruno Fabris; Claudio Celeghini; Silvano Capitani; Giorgio Zauli
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

5.  Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?

Authors:  Simon S Cross; Zhiyong Yang; Nicola J Brown; Sabapathy P Balasubramanian; Clair A Evans; Julia K Woodward; Helen L Neville-Webbe; Jenny M Lippitt; Malcolm W R Reed; Robert E Coleman; Ingunn Holen
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

Review 6.  Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L.

Authors:  Roberta Di Pietro; Giorgio Zauli
Journal:  J Cell Physiol       Date:  2004-12       Impact factor: 6.384

7.  Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34+ cells).

Authors:  G Zauli; M C Re; G Furlini; M Giovannini; M La Placa
Journal:  J Gen Virol       Date:  1992-02       Impact factor: 3.891

8.  Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2.

Authors:  Simone H Mangan; Ann Van Campenhout; Catherine Rush; Jonathan Golledge
Journal:  Cardiovasc Res       Date:  2007-08-02       Impact factor: 10.787

9.  Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo.

Authors:  Giorgio Zauli; Federica Corallini; Fleur Bossi; Fabio Fischetti; Paolo Durigutto; Claudio Celeghini; Francesco Tedesco; Paola Secchiero
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

10.  TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors.

Authors:  Giorgio Zauli; Erika Rimondi; Susanna Stea; Fabio Baruffaldi; Marco Stebel; Carlotta Zerbinati; Federica Corallini; Paola Secchiero
Journal:  J Cell Physiol       Date:  2008-01       Impact factor: 6.384
View more
  1 in total

Review 1.  Clinical perspectives of TRAIL: insights into central nervous system disorders.

Authors:  Veronica Tisato; Arianna Gonelli; Rebecca Voltan; Paola Secchiero; Giorgio Zauli
Journal:  Cell Mol Life Sci       Date:  2016-02-24       Impact factor: 9.261
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.